We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $11.1B
1-Year Est. Return 207.82%
This Fund
S&P 500
This Quarter Est. Return
+5.61%
1 Year Est. Return
+207.82%
3 Year Est. Return
+512.05%
5 Year Est. Return
+1,035%
10 Year Est. Return
+45,230.58%
AUM
$287M
AUM Growth
-$3.65M
Cap. Flow
+$64.2M
Cap. Flow %
22.39%
Top 10 Hldgs %
66.86%
Holding
42
New
13
Increased
6
Reduced
16
Closed
4

Top Buys

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$22.6M
2
GILD icon
Gilead Sciences
GILD
+$15.8M
3
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
+$12.3M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$11.4M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$11M

Top Sells

Rank Stock Value
1
LJPC
La Jolla Pharmaceutical Company
LJPC
+$10.2M
2
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
+$5.54M
3
DERM
Dermira, Inc.
DERM
+$4.42M
4
INNL
Innocoll Holdings plc Ordinary Shares
INNL
+$4.16M
5
IBRX icon
ImmunityBio
IBRX
+$3.81M

Sector Composition

Rank Sector Weight
1 Healthcare 86.13%
2 Miscellaneous 13.87%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TRIL
26
DELISTED
Trillium Therapeutics Inc.
TRIL
$2.12M 0.74%
228,697
-25,000
-10% -$211K
SRPT icon
27
CALL
Sarepta Therapeutics
SRPT
$2.19B
$2.01M 0.7%
307,500
+260,200
+550% +$4.55M
VCEL icon
28
Vericel Corp
VCEL
$2.04B
$1.61M 0.56%
275,000
-860,120
-76% -$2.41M
IBRX icon
29
ImmunityBio
IBRX
$8.44B
$1.6M 0.56%
194,912
-404,375
-67% -$3.81M
EGLT
30
DELISTED
Egalet Corporation
EGLT
$1.6M 0.56%
233,334
-199,272
-46% -$1.56M
AEGR
31
DELISTED
Aegerion Pharmaceuticals
AEGR
$1.14M 0.4%
306,800
-426,325
-58% -$2.64M
CRVS icon
32
Corvus Pharmaceuticals
CRVS
$1.1B
$1.08M 0.38%
+74,800
New +$1.07M
CLLS
33
Cellectis
CLLS
$161M
$688K 0.24%
25,000
-10,000
-29% -$241K
XNTK icon
34
PUT
State Street SPDR NYSE Technology ETF
XNTK
$1.87B
$670K 0.23%
+750,000
New +$36.9M
GYRE icon
35
Gyre Therapeutics
GYRE
$696M
$120K 0.04%
636
– –
PGEN icon
36
CALL
Precigen
PGEN
$2.48B
$60K 0.02%
+201,800
New +$6.35M
OEF icon
37
PUT
iShares S&P 100 ETF
OEF
$20.1B
$51K 0.02%
+250,000
New +$21.8M
AXDX
38
DELISTED
Accelerate Diagnostics
AXDX
– –
-11,289
Closed -$2.43M
TNXP icon
39
Tonix Pharmaceuticals
TNXP
$200M
– –
0
– -$2.61M
SIOX
40
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
– –
-38,384
Closed -$5.54M
ADYX
41
DELISTED
Adynxx Inc
ADYX
– –
-13,985
Closed -$1.8M
INNL
42
DELISTED
Innocoll Holdings plc Ordinary Shares
INNL
– –
-501,722
Closed -$4.16M
1
2

Similar funds

GI
GAMCO Investors Greenwich, Connecticut $11.1B AUM 41.79% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return
BEI
Benjamin Edwards Inc Clayton, Missouri $11B AUM 18.22% 1-Year Est. Return
VNIM
Vaughan Nelson Investment Management Houston, Texas $11.3B AUM 53% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
GJL
Gendell Jeffrey L $11.3B AUM 163.05% 1-Year Est. Return
LCAM
London & Capital Asset Management London, United Kingdom $10.9B AUM 39.88% 1-Year Est. Return

Avoro Capital Advisors's Q1 2016 Portfolio in Review

As of Q1 2016, Avoro Capital Advisors held 42 positions worth $287M, down 1.3% from $290M the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Avoro Capital Advisors deployed $64.2M of net new capital in Q1 2016, opening 13 new positions and adding to 6 existing holdings. Its largest new stake was BioMarin Pharmaceuticals: 277,272 shares worth $22.9M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was La Jolla Pharmaceutical Company, an estimated $10.2M trimmed.

  • Avoro Capital Advisors's largest Q1 2016 buy was BioMarin Pharmaceuticals: 277,272 shares worth $22.9M.
  • Avoro Capital Advisors added most to Sarepta Therapeutics in Q1 2016, an estimated $11.4M increase.
  • Avoro Capital Advisors's biggest Q1 2016 reduction was La Jolla Pharmaceutical Company, cutting an estimated $10.2M.
  • Avoro Capital Advisors fully exited Sio Gene Therapies Inc. Common Stock in Q1 2016, selling an estimated $5.54M.
  • Avoro Capital Advisors's ten largest holdings make up 67% of its $287M portfolio in Q1 2016.
  • Avoro Capital Advisors opened 13 new positions and closed 4 in Q1 2016.
  • Avoro Capital Advisors's portfolio value fell 1.3% quarter-over-quarter to $287M.

Based on Avoro Capital Advisors's 13F filing for Q1 2016, filed 16 May 2016.